| |
James Kramer joins Bioreliance
James J. Kramer, Ph.D, joins BioReliance as Vice President of
Operations, U.S. Biologics. In his new position, Dr. Kramer is the US
Biologic Services Value Stream leader for the company and has direct
ownership for Program Management, Quality, GMP-Cell Banking, Clearance
Services, Molecular Biology, Cell Biology Microbiology, Virology,
In-Vivo Studies, Support Services and Facilities.
Click here to read the
press release.
BioReliance Corporation Launches iNet™ for Online Results Tracking of Biological Safety Tests
BioReliance is pleased to announce to US customers the release of iNet, a proprietary information technology system for submitting and
tracking test article details via a controlled and secure Internet access from any location worldwide. Now you can view the status of
current and past studies, keep in formed of when testing will be completed, download reports, and allow your colleagues to view the
status of your tests. Click here to read the press release.
|
|
|
|
|
BioReliance has been performing virus clearance studies for the majority of blood and plasma derivatives since 1984, and were the first company to offer the Western blot for use in TSE clearance studies.
|
BioReliance has been performing virus clearance studies for the majority of blood and plasma derivatives since 1984, and were the first company to offer the Western blot for use in TSE clearance studies. Viral clearance studies are conducted to establish the efficacy of a process to remove and / or inactivate potential contaminants, and are thus a key component in assessing the safety of biopharmaceutical products.
|
|
|
|
|
|
|
|
|
Purity Tests
Analytical Testing
Stability Testing
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antibody Screening |
|
|
|
|
|
|
|
|
|
|  |
|
|
